MODS, Septic Shock, Severe Sepsis
Conditions
Brief summary
The study will enhance the theory in the frame of reference on the efficacy of Ulinastatin while managing sepsis and subsequent morbidity and mortality. Moreover, the present study will explore Ulinastatin's prophylactic role in progression of multiple organ dysfunctions. Furthermore, the study will have the clinical implications in predicting the ICU admitted patient's stay and related cost in the context of new drug. Current researches will explore the new dimensions in Pakistan's healthcare facilities, paving the way of future academics to analyze it in order to enhance healthcare outcomes.
Detailed description
The current study is a randomised clinical trial with the aim of exploring the following objectives in the context of Pakistan: * To determine the efficacy of Ulinastatin in preventing the progression of Sepsis to Severe Sepsis and septic shock. * To assess the role of Ulinastatin in preventing the onset of MODS in sepsis-induced patients. * To investigate the impact of Ulinastatin on sepsis associated mortality and morbidity. * To explore the role of Ulinastatin in reducing ICU stays and associated costs in defined patients. * To provides a condensed basis to understand ULINASTATIN as a sepsis management drug.
Interventions
DRUGUlinastatin
Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
Sponsors
Jinnah Postgraduate Medical Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Age \>18 or \<60 * Sepsis, and severe sepsis, as defined in operational definitions * Patients voluntarily agreed to participate in the study after informed consent
Exclusion criteria
* Fulminant hepatic failure * Acute cerebrovascular accidents * Acute poisoning * Chronic Kidney Disease stage 5 * Diagnosed case of immune thrombocytopenia * Low output cardiac failure, with left ventricular ejection fraction \<20% * Advance chronic obstructive pulmonary disease on long term oxygen therapy * Lactation or pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect on 28 days mortality | During the 28 days of enrollment | To investigate the impact of Ulinastatin on sepsis associated mortality. |
| Prevention of MOD's in patients with sepsis | Day 1 of enrollment | To assess the role of Ulinastatin in preventing the onset of MODS in sepsis-induced patients. Sepsis is defnied as evidence of infection (positive culture of blood, Urine, Tracheal) or suspected infection (by a physician) plus 2 out of 4 criteria's of SIRS. MODS is presence of two or more organ dysfunction with scoring ≥2 of each organ as per Sequential Organ Failure Assessment (SOFA) score. |
| Effect on in-hospital mortality | During first 48 hours of hospital stay after enrollment | To investigate the impact of Ulinastatin on sepsis associated mortality. |
| Effect on 7 days mortality | During the 7 days of enrollment | To investigate the impact of Ulinastatin on sepsis associated mortality. |
| Effect on 14 days mortality | During the 14 days of enrollment | To investigate the impact of Ulinastatin on sepsis associated mortality. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of days in ICU | Up to 28 days after enrollment | To explore the role of Ulinastatin in reducing ICU stays. |
| Prevention of Severe Sepsis in patients admitted with Sepsis | Up to 28 days after enrollment | To determine the efficacy of Ulinastatin in preventing the progression of sepsis to severe sepsis. Severe sepsis is sepsis as defined above plus at least one organ/system dysfunction scoring ≥ 2 as per Sequential Organ Failure Assessment (SOFA) score. |
| Prevention of Septic Shock in patients admitted with Sepsis | Up to 28 days after enrollment | To determine the efficacy of Ulinastatin in preventing the progression of sepsis to septic shock. Septic shock is persistent hypotension requiring vasopressors to maintain mean arterial pressure of 65mmHg or higher and a serum lactate level greater than 2mmol/L despite adequate volume resuscitation with 30ml/kg of crystalloid solution. |
| Number of days on mechanical ventilation | Up to 28 days after enrollment | To explore the role of Ulinastatin in reducing the number of days on mechanical ventilation |
Countries
Pakistan
Contacts
Primary ContactZeeshan Ali, FCPS
Backup ContactShamim Kausar, FCPS
Outcome results
None listed